Delirium Clinical Trial
Official title:
Combined Activity and Cognitive Intervention to Optimize Recovery From Critical Illness in ICU Survivors: COMBAT-ICU Trial
Verified date | May 2024 |
Source | The University of Hong Kong |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This mixed-methods study comprising a 3-arm pilot RCT and a qualitative study aims to investigate the preliminary effects and feasibility of a home-based combined activity and cognitive intervention for ICU survivors (COMBAT-ICU). Adopting a 3-arm design with COMBAT-ICU, exercise and attention placebo study arms will enable us to evaluate the added effects, if any, of the novel combined intervention compared with the standard exercise-only rehabilitation strategy and attention placebo. Data triangulation from quantitative and qualitative aspects can facilitate result interpretation. The study's objectives are: 1. To evaluate the preliminary effects of the COMBAT-ICU intervention for ICU survivors on PICS, physical, mental and cognitive outcomes, HRQoL, unplanned re-hospitalisation rate, and mortality. 2. To explore the feasibility and acceptability of the COMBAT-ICU intervention and ICU survivors' intervention engagement experience. The hypothesis of the first objective is that upon completion of the COMBAT-ICU intervention, ICU survivors will have reduced PICS, improved physical function, mental health, cognition and HRQoL, and reduced unplanned readmissions and mortality compared with the exercise and attention placebo groups at post-intervention and 3 months thereafter. While the hypothesis of the second objective is that the COMBAT-ICU intervention is feasible and acceptable for ICU survivors.
Status | Enrolling by invitation |
Enrollment | 60 |
Est. completion date | February 12, 2026 |
Est. primary completion date | November 12, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Chinese adults aged =18 2. has been admitted to ICU for at least 4 days 3. discharged home 4. able to perform basic activities of daily living before ICU admission 5. living with family 6. has an electronic device that can access the internet (patient/family) 7. able to walk for at least 10 metres (assisted or unassisted) Exclusion Criteria: 1. cannot read Chinese 2. has musculoskeletal injury precluding exercise training 3. is receiving structured out-patient pulmonary or cardiac rehabilitation after discharge 4. has clinically evident dementia or significant impairment from an acute brain problem (e.g. traumatic brain injury, stroke, subarachnoid haemorrhage or hypoxic brain injury) that precludes following the study protocol 5. has prolonged length of stay (=28 days) in the step-down wards |
Country | Name | City | State |
---|---|---|---|
Hong Kong | The School of Nursing | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
The University of Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient-reported PICS | The 18-item Post-Intensive Care Syndrome Questionnaire (PICSQ) will be used to measure the extent of PICS. The PICSQ consists of 3 subscales, physical, cognitive and mental, and is rated on a 4-point Likert scale ranging from 0 to 3. It has good internal consistency (Cronbach's alpha = 0.93). Its criterion validity is evidenced by its strong correlation with frailty and HRQoL measures, and factor analysis confirmed its construct validity. | At baseline (T0), immediate post-intervention: 8 weeks (T1) and 3 months post-intervention (T2) | |
Secondary | 6-Minute Walk Test (6MWT) | 6MWT will be used to evaluate aerobic capacity and endurance. Standard measurement guidelines will be followed, and the distance walked will be recorded. | At baseline (T0), immediate post-intervention: 8 weeks (T1) and 3 months post-intervention (T2) | |
Secondary | Time-Up-Go test | Time-Up-Go test will be used to measure functional mobility, assessed by the time it takes to stand up, walk a distance of 10 feet, turn, walk back and sit down. | At baseline (T0), immediate post-intervention: 8 weeks (T1) and 3 months post-intervention (T2) | |
Secondary | Short Physical Performance Battery | The Short Physical Performance Battery will be used to assess functional capacity. It consists of 3 timed tasks: standing balance, walking speed and chair stand tests. | At baseline (T0), immediate post-intervention: 8 weeks (T1) and 3 months post-intervention (T2) | |
Secondary | Grip strength | Handgrip strength will be assessed by a dynamometer to evaluate muscle strength of upper limbs. | At baseline (T0), immediate post-intervention: 8 weeks (T1) and 3 months post-intervention (T2) | |
Secondary | Digit Span test | The Digit Span test will be used to measure short-term and working memory. | At baseline (T0), immediate post-intervention: 8 weeks (T1) and 3 months post-intervention (T2) | |
Secondary | Colour Trails Test | Colour Trails Test to measure executive function and attention. It has two parts: part 1 assesses visual-motor processing speed and attention, and part 2 sequencing and mental flexibility in addition to processing speed and attention. | At baseline (T0), immediate post-intervention: 8 weeks (T1) and 3 months post-intervention (T2) | |
Secondary | Montreal Cognitive Assessment | The Montreal Cognitive Assessment will be used to assess global cognition | At baseline (T0), immediate post-intervention: 8 weeks (T1) and 3 months post-intervention (T2) | |
Secondary | Patient Health Questionnaire-9 | The Patient Health Questionnaire-9 will be used to measure the frequency of depressive symptoms in the past 14 days. Its 9 items are rated on a 4-point scale ranging from 0 to 3, with higher sum scores indicating more depressive symptoms. | At baseline (T0), immediate post-intervention: 8 weeks (T1) and 3 months post-intervention (T2) | |
Secondary | Generalized Anxiety Disorder Scale-7 | The Generalized Anxiety Disorder Scale-7 will be used to measure anxiety levels. Ratings on a 4-point scale (0-3) indicate the frequency of anxiety symptoms in the past 14 days, with higher total scores representing greater anxiety.
HRQoL: The EuroQol Five Dimensions Five Levels (EQ-5D-5L) will be used to measure HRQoL. It consists of two parts: EQ-5D descriptive system and EQ visual analogue scale. The first part uses 5 levels to indicate a participant's health state on 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression - and the second part is an additional self-rated health item rated on a visual analogue scale ranging from 0-100. |
At baseline (T0), immediate post-intervention: 8 weeks (T1) and 3 months post-intervention (T2) | |
Secondary | EuroQol Five Dimensions Five Levels (EQ-5D-5L) | EQ-5D-5L will be used to measure health-related quality of life. It consists of two parts: EQ-5D descriptive system and EQ visual analogue scale. The first part uses 5 levels to indicate a participant's health state on 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression - and the second part is an additional self-rated health item rated on a visual analogue scale ranging from 0-100. | At baseline (T0), immediate post-intervention: 8 weeks (T1) and 3 months post-intervention (T2) | |
Secondary | Unplanned hospital readmission | Hospital utilisation data will be monitored from T0 to T2 through electronic medical record review. | From baseline (T0) to 3 months post-intervention (T2) | |
Secondary | mortality | mortality will be monitored from T0 to T2 through electronic medical record review. | From baseline (T0) to 3 months post-intervention (T2) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04551508 -
Delirium Screening 3 Methods Study
|
||
Recruiting |
NCT05891873 -
Delirium in the (Neuro)Intensive/Critical Care in the Adult and Paediatric Czech Populations
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT04792983 -
Cognition and the Immunology of Postoperative Outcomes
|
||
Recruiting |
NCT06194474 -
Study on Biomarkers of Postoperative Delirium in Elderly Cardiac Surgery Patients
|
||
Completed |
NCT03095417 -
Improving the Recovery and Outcome Every Day After the ICU
|
N/A | |
Completed |
NCT05395559 -
Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
|
||
Terminated |
NCT03337282 -
Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
|
||
Not yet recruiting |
NCT04846023 -
Pediatric Delirium Screening in the PICU Via EEG
|
N/A | |
Not yet recruiting |
NCT04538469 -
Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
|
||
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Withdrawn |
NCT02673450 -
PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.
|
||
Recruiting |
NCT03256500 -
Transcranial Direct Current Stimulation for the Treatment of Delirium
|
N/A | |
Not yet recruiting |
NCT02892968 -
ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients
|
N/A | |
Completed |
NCT02890927 -
Geriatric-CO-mAnagement for Cardiology Patients in the Hospital
|
N/A | |
Recruiting |
NCT03165539 -
Cerebral Oxygen Desaturation and Post-Operative Delirium in Thoracic Surgical Patients
|
||
Completed |
NCT02518646 -
DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models
|
N/A | |
Completed |
NCT02554253 -
The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction
|
Phase 2 | |
Recruiting |
NCT02305589 -
The Clinical Changes Before and After Sugammadex in the Patients Undergoing Hip Surgery on the Aspect of Delirium
|
N/A | |
Completed |
NCT02628925 -
Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale
|
N/A |